Table 5. Stratified analysis of LMP7 gene codon 145 genotypes with chronic HCV infection.
| Stratified characteristics | Persistent infection [n (%)] |
Spontaneous Clearance [n (%)] |
Controls [n (%)] |
Controls/Persistent infection OR(95%CI)* |
Controls/Spontaneous clearance OR(95%CI)* |
Persistent infection/Spontaneous clearance OR(95%CI)* |
||||||||
| Gln/Gln | Gln/Lys +Lys/Lys | Gln/Gln | Gln/Lys +Lys/Lys | Gln/Gln | Gln/Lys +Lys/Lys | Gln/Gln | Gln/Lys +Lys/Lys | Gln/Gln | Gln/Lys +Lys/Lys | Gln/Gln | Gln/Lys +Lys/Lys | |||
| Age (y) | ||||||||||||||
| ≤30 | 26(46.4) | 30(53.6) | 45(54.9) | 37(45.1) | 71(67.6) | 34(32.4) | 1.00 | 2.13(0.99-4.56) | 1.00 | 1.20(0.59-2.44) | 1.00 | 1.47(0.74-2.95) | ||
| >30 | 54(46.2) | 63(53.8) | 67(62.6) | 40(37.4) | 84(70.0) | 36(30.0) | 1.00 | 1.91(1.02-3.55) | 1.00 | 1.11(0.57-2.16) | 1.00 | 1.94(1.12-3.34) | ||
| Gender | ||||||||||||||
| male | 54(43.9) | 69(56.1) | 76(60.3) | 50(39.7) | 109(69.4) | 48(30.6) | 1.00 | 2.19(1.24-3.89) | 1.00 | 1.03(0.57-1.86) | 1.00 | 2.02(1.21-3.38) | ||
| female | 26(52.0) | 24(48.0) | 36(57.1) | 27(42.9) | 46(67.6) | 22(32.4) | 1.00 | 1.47(0.61-3.56) | 1.00 | 1.25(0.52-2.99) | 1.00 | 1.30(0.60-2.82) | ||
| IDU | ||||||||||||||
| yes | 60(43.8) | 77(56.2) | 93(57.8) | 68(42.2) | 45(61.6) | 28(38.4) | 1.00 | 1.91(1.05-3.48) | 1.00 | 1.15(0.64-2.04) | 1.00 | 1.78(1.12-2.85) | ||
| no | 20(55.6) | 16(44.4) | 19(67.9) | 9(32.1) | 110(72.4) | 42(27.6) | 1.00 | 1.97(0.90-4.33) | 1.00 | 1.07(0.43-2.65) | 1.00 | 1.63(0.57-4.62) | ||
| Duration of drug use (y) | ||||||||||||||
| ≤5 | 28(47.5) | 31(52.5) | 50(64.9) | 27(35.1) | 112(72.3) | 43(27.7) | 1.00 | 2.86(1.41-5.78) | 1.00 | 1.22(0.61-2.47) | 1.00 | 2.23(1.09-4.58) | ||
| 5∼10 | 26(44.1) | 33(55.9) | 41(51.2) | 39(48.8) | 29(65.9) | 15(34.1) | 1.00 | 1.86(0.77-4.45) | 1.00 | 1.50(0.63-3.56) | 1.00 | 1.51(0.74-3.10) | ||
| ≥10 | 26(47.3) | 29(52.7) | 21(65.6) | 11(34.4) | 14(53.8) | 12(46.2) | 1.00 | 1.18(0.43-3.23) | 1.00 | 0.48(0.14-1.65) | 1.00 | 2.40(0.93-6.21) | ||
* Logistic regression model, adjusted by gender, age, injection drug user and duration of drug use.